Promoted Content
Promoted Content

Market Place

Market Place

Menu

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Prices
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              GlaxoSmithKline

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED KINGDOM United Kingdom

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              PHARMACEUTICAL MARKETING

              Participation Not Confirmed

              Update your events

              GSK Presents Phase 2b Data on Linerixibat for the Treatment of Cholestatic Pruritus in Primary Biliary Cholangitis (PBC)

              Contact the Supplier

              Lead Product(s): Linerixibat

              Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: GSK2330672

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable November 13, 2020

              Details:

              Data showed that targeting bile acid reuptake with linerixibat, an ileal bile acid transporter (IBAT inhibitor), could provide relief for patients with cholestatic pruritus in PBC.

              PharmaCompass__DigitalAd